Reticulum Cell Sarcoma after Renal Homotransplantation and Azathioprine and Prednisone Therapy

Doak, P. B.; Montgomerie, John Z.; North, J. D. K.; Smith, F.

doi:10.1136/bmj.4.5633.746

Cited by 143 publications

(36 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first reports of soft-tissue and lymphoproliferative malignancy among renal transplant recipients date back to the late 1960s. 1,2 As the variety of transplanted organs has grown and long-term survival is now expected, the range and severity of neoplasms have become a formidable medical challenge. The reported lifetime incidence of posttransplant malignancy varies, but overall the risk appears to be three to five times that of the general population.…”

Section: Introductionmentioning

confidence: 99%

A 30-Year Analysis of Colorectal Adenocarcinoma in Transplant Recipients and Proposal for Altered Screening

Johnson

Leverson

Pirsch

et al. 2007

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

A 30-Year Analysis of Colorectal Adenocarcinoma in Transplant Recipients and Proposal for Altered Screening

Johnson

Leverson

Pirsch

et al. 2007

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

show abstract

“…Since Doak et al first described malignant disease arising de novo in transplant recipients, 9 it has become well known that renal transplant recipients are prone to the development of malignancies. 1,2 Moreover, it is generally accepted that malignancy is a long-term complication of immunosuppression.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Outcomes of Immunosuppressed Renal Transplant Recipients with Malignancies

Gunji

Sakamoto

Kamura³

et al. 2001

Surgery Today

View full text Add to dashboard Cite

This study analyzes ten cases of malignancy in a cohort of 183 renal transplant recipients, examining surgical management, postoperative immunosuppressive therapy, and long-term outcome. One of these ten patients, who had malignant lymphoma of the jejunum, died of the neoplasm, but the other nine patients did not show any signs of tumor recurrence after removal. All of these nine patients, except for one who had transplant renal cell carcinoma (RCC), received the same dose of immunosuppressive agents after surgery for the malignant disease. Seven patients were still alive at the time of this report, six of whom had good transplant renal function. The findings of this study indicate that even if immunosuppressive agents predispose to the development of cancer, it is not necessary to reduce their dose after removal of the tumor.

show abstract

“…Since the first report of PTLD, reduction of immune suppression (RI) became the mainstay of treatment of these patients [20,21,22]. However, RI alone proved to be insufficient, resulting in only 1/16 partial responses in a prospective trail of sequential RI, interferon α-2B, and chemotherapy in PTLD patients [23].…”

Section: Discussionmentioning

confidence: 99%

Primary Intestinal Hodgkin Lymphoma Mimicking Intraabdominal Abscess in a Renal Transplant Recipient: A Case Report

Mihaljević¹,

Vukovic²,

M³

et al. 2016

Oncol Res Treat

View full text Add to dashboard Cite

Introduction: Post-transplant lymphoproliferative disease (PTLD) comprises a variety of lymphoid and plasma cell disorders arising in patients with a solid organ transplant. Monomorphic lymphomas represent the most significant part of this wide spectrum, with the overall risk rising with the aggressiveness of lymphoid proliferation in comparison to the general population. The development of Hodgkin lymphoma is very rare in transplant recipients, comprising less than 6% of all monomorphic PTLD, while cases of primary intestinal Hodgkin lymphoma in these circumstances are anecdotal. Case Report: We describe an exceptional case of intestinal Hodgkin lymphoma mimicking an intra-abdominal abscess that developed in a transplant recipient 19 years after kidney transplantation. By presenting this case, we wish to emphasize the importance of suitable diagnostic pathways in transplant recipients experiencing prolonged fever episodes or masses of unknown origin, thus raising the awareness of possible PTLD development in such patients. Conclusion: The lack of information about transplant recipients with Hodgkin PTLD regarding the site of involvement and type of treatment suggests the necessity of conducting larger international studies aimed at providing further insight into this particular group of patients.

show abstract

Reticulum Cell Sarcoma after Renal Homotransplantation and Azathioprine and Prednisone Therapy

Cited by 143 publications

References 15 publications

A 30-Year Analysis of Colorectal Adenocarcinoma in Transplant Recipients and Proposal for Altered Screening

A 30-Year Analysis of Colorectal Adenocarcinoma in Transplant Recipients and Proposal for Altered Screening

Long-Term Outcomes of Immunosuppressed Renal Transplant Recipients with Malignancies

Primary Intestinal Hodgkin Lymphoma Mimicking Intraabdominal Abscess in a Renal Transplant Recipient: A Case Report

Contact Info

Product

Resources

About